At Evolve, we have extensive experience managing patent strategy for pharmaceutical products at all stages of the pipeline, from protecting early platform development to supporting continued life-cycle management investment for on-market products. We therefore have first-hand experience of ensuring that IP strategy is aligned with your business goals. We can complement your in-house team to provide additional resource and expertise when you need it. We can also assist with highly time-sensitive due diligence work, including reviews of complex international portfolios.
Building your IP portfolio
Our attorneys have experience managing complex global IP portfolios for platform technologies, clinical stage assets and on-market products. We know how to tailor and adapt the IP strategy to your business needs. We can assist with drafting all types of pharmaceutical IP, including composition of matter, with experts in both the small molecule pharmaceutical and biologics fields. We can also assist in advising on strategy, drafting and prosecuting clinical stage IP including formulation, dose, polymorph, biomarker and manufacturing patents.
Competitive intelligence, mitigating risks and freedom to operate
IP strategy can be as much about keeping informed of the competition as it is about building your own portfolio. We can help you monitor and assess the competitive landscape to identify potential IP risks and opportunities, from providing an earlier view on the landscape to help initial investment decisions, to deep dives into your technology areas of interest.
We can also conduct freedom-to-operate analyses to ensure your research and development activities do not infringe on the IP rights of others. While IP disputes should generally be avoided, we can handle any contentious matters that arise, such as patent infringement claims or oppositions, and develop strategies to resolve them effectively.
In-licensing and acquisition due diligence
We know that in the pharmaceutical sector deals are often fast-moving and high pressure. We can complement your in-house team to assist in the due diligence process, as well as provide expert guidance leveraging our experience in particular technology areas, including advanced therapies and AI-assisted drug development. We will provide you with clear and practical advice so that you can understand any risks and opportunities and effectively communicate these with your internal stakeholders. We can work with you to conduct thorough loss of exclusivity, validity, chain of title, and freedom to operate analysis, as well as review of IP provisions.
Fractional IP counsel
Why fractional IP counsel for established pharma? Even large in-house teams have peaks, gaps and projects that need senior cover, such as a new programme, a portfolio review or a period of high deal activity. Our fractional IP counsel model places a named senior patent attorney inside your team. Our patent directors have done the job inside pharma, so they bring the real-world industry experience that you only get working in-house and can join your team with very little induction. Our own AI tools, developed by our attorneys specifically for pharma and biotech IP, support validity, prosecution, due diligence and invention spotting work, so we can look at more, in more depth, while our attorneys make the judgement calls. With our specialist team behind them, they can take on a whole programme rather than a single task, something a lone consultant cannot do and a traditional IP firm rarely offers, with a global strategic approach.
Read more
